2019 Call for Applications - NOW OPEN. OBIO CAAP® is a unique, industry-led initiative that provides selected high-potential Ontario health science companies with mentoring, strategic guidance and access to an expansive network of health science industry experts and investors to enhance the ability of OBIO CAAP companies to secure financing.
Last week, OBIO announced the successful completion of the OBIO Canadian Health Investment Showcase in New York City. Check out this recap and photo gallery of the event.
The Ontario Bioscience Innovation Organization (OBIO®) is honoured to announce the conclusion of the successful Canadian Health Investment Showcase which took place in New York, NY, on November 5 and 6, 2018.
Candidates like these are currently interviewing for placements for this January’s H2BB cohort. Don't miss out on the best and brightest business talent!
Co-op students for January internships are already securing positions. OBIO H2BB can help connect you to top tier talent from programs with January internships including McMaster’s Master of Biomedical Discovery and Commercialization, University of Toronto’s Master of Biotechnology and McMaster’s DeGroote Co-op MBA. Students from these programs may qualify for Ontario’s Co-operative Education Tax Credit.
This week, as part of the TCI Network 2018 Global Conference, OBIO CEO Gail Garland led a session with Canadian and international experts on our domestic health cluster.
On October 3rd, OBIO hosted a CEO2CEO event attended by over 30 CEOs and senior health science company executives
In response to industry demand, OBIO is proud to announce the launch of the OBIO Job Board, its latest ‘Access to Talent’ program.
The OBIO Job Board will be hosted on the newly revamped OBIO website and will be free for all health science companies wishing to post their latest health science job openings.
On September 18th, OBIO organized a workshop with two industry experts and provided the CFO perspective on budgeting for start-up and growing health science companies.
John Jordan (CFO, RNA Diagnostics) and Jim Cooke (Partner, Stoneybridge Partners) addressed 3 main areas – how to build a robust budget, how to present a budget to the board and to investors and how to manage a budget.
On Wednesday, September 5th, OBIO hosted Toshio Sugano, the Chief Investment Officer of the Biomedical Development Board of Taiwan, who met with a collection of Canada’s most esteemed investors and some of its highest potential health science companies.
If you are considering hiring a new graduate or intern this coming January, it is a good idea to get started now. OBIO H2BB is constantly sourcing new early career talent from top business and innovation programs.
On Tuesday, August 27th, OBIO hosted a delegation of distinguished scientists from National Cheng Kung University to meet with representatives from the Ontario health science industry including OIRM and CCRM, and the provincial government.
OBIO has pre-screened 18 business-experienced candidates ready to help your company scale and grow. These high-quality recent business (MBA; M.Mgmt; M. Mgt Innovation, etc.) graduates and co-op students have the Business Development skills you need.
OBIO Health To Business Bridge™ program (H2BB™) has 20 pre-screened business-experienced candidates ready to help your company scale and grow. These high-quality recent business graduates and co-op students have the Business Development skills you need.
As part of the Federal Government’s regulatory reform agenda, the health science industry has been announced as one of three sectors targeted for regulatory review. This is an unprecedented opportunity for health science companies to provide direct, open-ended feedback to the federal government on the regulatory challenges and hurdles that directly (or indirectly) impact your business.
Last week, OBIO hosted a day of meetings with Dr. Jonathan Shieh, Executive Director, Science and Technology Division of the Taipei Economic and Cultural Office which brought Dr. Shieh together with officials from the Ontario government, Ministry of Economic Development, Job Creation and Trade, as well as high-potential Ontario health science companies.
OBIO H2BB is now offering top graduate-level, business-trained students and recent graduates, who will expand your business, marketing and/or finance strategies through market research, investor targeting, or conference preparation.
On June 25th, OBIO organized a workshop with two industry leaders and provided a VC perspective on how they valuate start-up companies and on how this is translated into a deal structure, featuring presentations by Richard Meadows (General Partner, BioInnovation Capital Fund & OBIO Board Director) and Andy Haigh (COO, Adapsyn Bioscience).
On the evening of Tuesday, June 26th, David Cayea (COO, PlantForm Corporation) shared how PlantForm had developed a strategy for securing non-dilutive funding, through which they had raised over $6.5M in funding, via grants and research contracts alone.
On June 26th, OBIO hosted Building Your Early-Stage Strategy Toolbox featuring sessions on formulating a non-dilutive funding strategy, early-stage business strategies, and preparing investor materials.
On June 14th, OBIO hosted Dr. Yuan Fang (VP Regulatory Affairs, Quality and Manufacturing; Focal Healthcare Inc.) who spoke about his perspective on the recent changes at the U.S. Food and Drug Administration (FDA).
During his lively and highly engaging presentation on June 12, ‘Strategic Marketing & Commercialization Plans for Early Stage Companies,’ Dr. Brian Jahns (Senior VP, Commercial and Business Development at Trillium Therapeutics Inc) discussed approaches for developing strategies and the importance of scenario planning.
Executives from Ontario’s healthcare sector say they could benefit from a network of early adopter institutions and a capital fund that invests directly in health science companies preparing to commercialize their products and market them globally as they scale their businesses in Canada.
On June 14th, get behind-the-scenes on the recent changes at the FDA and learn more about how regulatory process changes affect your company.
On May 10, 2018, Medical Device Playbook 2018 Toronto, co-hosted by Starfish Medical and OBIO, drew a standing-room only audience of 170 health science industry professionals, from company executives, to QA, regulatory and R&D engineering experts from start-ups, manufacturers, consultancies, regulatory and academic organizations.
On May 3, OBIO welcomed health science leaders, CEOs and the investment community to the tenth annual OBIO Leadership Event, also saw the launch of Use It or Lose It: Industry Solutions to Ontario's Commercialization Gap, OBIO's 2018 Industry Report.
Canada’s premiere innovation and commercialization event for medical device professionals, co-hosted by Starfish Medical and OBIO, Medical Device Playbook 2018 is coming to the MaRS Discovery District on May 8, 2018.
This week, in Part 2 of a blog that began last week, we review the Niagara Emerging Health Science Company Forum, held in Niagara-on-the-Lake on Feb 1-2, 2018.
The forum brought together CEOs and senior executives from high potential Canadian health science companies with senior leadership from American investors and strategics in beautiful Niagara-on-the-Lake for two days of panel presentations, executive roundtables, and networking dinners.
OBIO is working to develop a model that will advance early access to the Ontario market. Critical to the development of this initiative is the ability to quantify the Ontario health science technology pipeline by category and stage of readiness to address the barriers to market access.
Michael Greeley, Co-Founder and General Partner at Flare Capital Partners, an early stage healthcare technology venture firm, and a Founding General Partner Flybridge Capital Partners blogged about Ontario's Health Tech Scene. Michael was a panelist at OBIO's recent Niagara on the Lake Health Sciences Emerging Company Forum, and wrote about his overall impression of the Ontario's emerging health tech companies.